EGFR
Assets acting on this target.
- Class
- EGFR tyrosine kinase inhibitor
Epidermal growth factor receptor (EGFR) is a transmembrane protein belonging to the ErbB family of receptor tyrosine kinases. When natural ligands such as epidermal growth factor bind its extracellular domain, EGFR pairs with itself or a related receptor, activating an intracellular kinase domain that triggers signaling cascades controlling cell growth, survival, and division. In many epithelial cancers, EGFR is overactive because of gene mutation, amplification, or overexpression, driving uncontrolled proliferation. Blocking EGFR activity, either with small-molecule tyrosine kinase inhibitors that occupy the kinase's ATP-binding pocket or with antibodies that prevent ligand binding, interrupts this growth signal and can slow or halt tumor progression. Because tumors frequently acquire secondary mutations within the kinase domain that render earlier inhibitors ineffective, successive generations of EGFR-directed agents have been designed to retain potency against these resistant forms, including mutations affecting the gatekeeper residue or exon 20 insertions. EGFR-targeted therapy is most established in non-small cell lung cancer harboring activating mutations, but the target also matters in other epithelial malignancies. Because EGFR is expressed on normal epithelial tissues, particularly skin and gut lining, its inhibition characteristically produces class-related toxicities such as rash and diarrhea, an on-target consequence of blocking a pathway also needed for normal tissue maintenance.
Related mechanisms
EGFR drugs compared
42 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Cetuximab | Eli Lilly, Merck KGaA | monoclonal antibody | Approved | Approved in Head and Neck Squamous Cell Carcinoma; Approved in Metastatic Colorectal Cancer |
| Erlotinib | Cheplapharm Arzneimittel GmbH | small molecule | Approved | Approved in Non-Small Cell Lung Cancer; Approved in Pancreatic Cancer |
| Gefitinib | AstraZeneca | small molecule | Approved | Approved in Non-Small Cell Lung Cancer |
| Lazertinib | Johnson & Johnson, Yuhan Corporation | small molecule | Approved | Approved in Non-Small Cell Lung Cancer |
| OsimertinibTagrisso | AstraZeneca | small molecule | Approved | Approved in Non-Small Cell Lung Cancer |
| SunvozertinibZegfrovy | AstraZeneca, Dizal Pharmaceuticals | small molecule | Approved | Approved in Non-Small Cell Lung Cancer |
| Almonertinib | Glenmark Pharmaceuticals Ltd., Hansoh Pharmaceutical Group | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Andamertinib | Avistone Biotechnology | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Asandeutertinib | TYK Medicines, Inc. | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Becotatug | Shanghai JMT-Bio | monoclonal antibody | Phase 3 | Phase 3 in Colorectal Cancer; Phase 3 in Non-Small Cell Lung Cancer |
| Befotertinib | Betta Pharmaceuticals Co., InventisBio | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| CPO301 | Conjupro Biotherapeutics, Inc. | antibody-drug conjugate | Phase 3 | Phase 3 in Breast Cancer; Phase 3 in Head and Neck Squamous Cell Carcinoma; Phase 3 in Non-Small Cell Lung Cancer |
| FHND9041 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Shanghai Henlius Biotech | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Furmonertinib | Allist Pharmaceuticals, ArriVent BioPharma | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Icotinib | Betta Pharmaceuticals Co. | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Limertinib | Innovent Biologics, Jiangsu Aosaikang Pharmaceutical | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Pruvonertinib | Suzhou Puhe Pharmaceutical Technology Co., LTD | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Rezivertinib | Beta Pharma, Inc. | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Rilertinib (SH-1028) | Nanjing Sanhome Pharmaceutical | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Zipalertinib | Cullinan Therapeutics Inc., Taiho Pharmaceutical | small molecule | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| Pimurutamab | Shanghai Henlius Biotech | monoclonal antibody | Phase 2/3 | Phase 2/3 in Non-Small Cell Lung Cancer |
| ZorifertinibZorifer | Alpha Biopharma (Jiangsu) Co., Ltd. | small molecule | Phase 2/3 | Phase 2/3 in Non-Small Cell Lung Cancer |
| BEBT-109 | BeBetter Med | small molecule | Phase 2 | Phase 2 in Non-Small Cell Lung Cancer |
| JS111 | Shanghai Junshi Bioscience | small molecule | Phase 2 | Phase 2 in Non-Small Cell Lung Cancer |
| Sutetinib | Teligene US | small molecule | Phase 2 | Phase 2 in Non-Small Cell Lung Cancer |
| ANS02 | Avistone Biotechnology | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| BBT-207 | Parataxis Korea, Inc. | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| BH-30643 | BlossomHill Therapeutics | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| BPI-361175 | Betta Pharmaceuticals Co. | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| Dositinib mesylate | Henan Genuine Biotech | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| DZD6008 | Dizal Pharmaceuticals | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| H002 | RedCloud Bio | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| JIN-A02 | J Ints Bio | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| PH009-1 | Suzhou Puhe Pharmaceutical Technology Co., LTD | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| Silevertinib | Black Diamond Therapeutics, Inc. | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer; Phase 1/2 in Non-Small Cell Lung Cancer with EGFR Mutations |
| STX-241 | Pierre Fabre Medicament | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| VRN110755 | Voronoi, Inc | small molecule | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| ALX2004 | ALX Oncology Inc. | antibody-drug conjugate | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |
| AST2303 | Allist Pharmaceuticals | small molecule | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |
| EPI-326 | EpiBiologics | bispecific antibody | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |
Showing the 40 furthest-developed of 42 drugs. The roster below lists them all, with filters.